Another spin on the roulette wheel.. encouraging progress. Am hoping we see substance soon. Its being conducted by the same group already running a Phase II, which suggests something (not sure what yet)..
thinking about how this trial is designed, i think the endpoints (other than toxicity) will be totally uninterpretable and will convince neither the fda nor a potential partner. if a patient does well (relative to the natural history of atc), will it have been due to selection bias of patients (only the willing and able best patients enrolled on the study). due to the chemo, due to the radiation, due to the study drug? how will one know except for the always weak method of comparing to a historical control (nobody who matters buys this comparison)?